See what your peers are saying about iovera°.
William Barrett, MD and Jana Flener, PA-C
"When I saw the results of this, I was actually very impressed. It’s fairly dramatic and I think it’s worthwhile to have people see that experience and see what the patient goes through."
William Barrett, MD
"iovera˚ has really changed the way I approach the discussion with the patient as we are talking about what it means to have a knee replacement and how we’re going to manage their pain."
Jana Flener, PA-C
Pieter Vreede, MD
"Instead of having days' worth of pain control, we're now talking about at the very minimum weeks, but more often months. This allows us to provide much better postoperative pain control, allowing people to go through therapy and get through the entire postoperative process in much greater comfort. We were so impressed with the results, it was pretty easy to incorporate into the practice. It was hard to resist the changes that this new approach provided in terms of pain control and better patient outcomes. . . . Try it—really just try it. It really works and you'll be impressed with how well it works."
Sean McMillan, DO
Burlington Township, NJ2020
"Providing my patients non-surgical options to minimize pain associated with knee OA is huge. The iovera° system allows me to provide pain relief for patients who may not be candidates for knee replacements and are suffering with knee pain. For my TKA patients, iovera° treatment promotes confidence in our opioid-sparing approach prior to the day of surgery. iovera° provides analgesia for postoperative TKA pain and, in my opinion, helps patients get over the ‘pain storm’ quicker during their recovery, without the need for significant opioid consumption."
Scott Sigman, MD
"Evidence continues to mount that patients can undergo a total knee replacement safely and with improved outcomes using an opioid-sparing approach. Our patients are undergoing an iovera° nerve block a week prior to surgery. We then use a long-acting anesthetic at the time of surgery to provide additional pain relief after surgery. In my experience, most of our patients are now going home the day of surgery and are walking independently within 1 week of surgery."
Joshua A. Urban, MD
"The iovera° technology (system) has significantly changed the way I treat patients with chronic or acute knee pain in my practice. It has reduced opioid consumption in these patients after surgery. Treatment with the iovera° system has helped me buy time in my chronic pain patients, and in patients who are not eligible for surgery. I have developed an ultrasound imaging procedure that has helped me better target the nerves that are contributing to my patients’ knee pain."
Pieter Vreede, MD
“We’ve been performing iovera° treatments for several years now and it is one of the few technological advances in anesthesia that addresses a need that, up to now, has not been successfully addressed -orthopedic procedures are at high risk of long-term opioid dependency/abuse. In the knee, iovera° provides long-term (up to 3 months) analgesia along with reduced opioid consumption, better knee flexion at all measured time intervals, and faster recovery. The future for iovera° is extremely bright as we learn how to successfully apply this technology in other surgical procedures.”
Vinod Dasa, MD
New Orleans, Louisiana2020
“Health care has faced significant disruptions and challenges over the past few years, which were exacerbated by COVID-19 challenges in 2020. As the system resets and finds a new normal, our expectations and demands will change accordingly. What was previously considered theoretical - outpatient opioid-free surgery - is now an expectation for my practice as we develop and deploy new innovations and workflows.”
IndicationThe iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. The iovera° system is not indicated for treatment of central nervous system tissue. The iovera° system’s “1x90” Smart Tip configuration (indicating one needle which is 90 mm long) can also facilitate target nerve location by conducting electrical nerve stimulation from a separate nerve stimulator.
Important Safety Information
ContraindicationsThe iovera° system is contraindicated for use in patients with the following:
- Cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud’s disease, and open and/or infected wounds at or near the treatment site
Potential ComplicationsAs with any surgical treatment that uses needle-based therapy and local anesthesia, there is a potential for site-specific reactions, including, but not limited to:
- Ecchymosis, edema, erythema, local pain and/or tenderness, and localized dysesthesia
Proper use of the device as described in the User Guide can help reduce or prevent the following complications:
- At the treatment site(s): injury to the skin related to application of cold or heat, hyper- or hypopigmentation, and skin dimpling
- Outside the treatment site(s): loss of motor function